MRM - MEDIROM Healthcare T... Stock Analysis | Stock Taper
Logo
MEDIROM Healthcare Technologies Inc.

MRM

MEDIROM Healthcare Technologies Inc. NASDAQ
$1.22 -11.31% (-0.16)

Market Cap $7.00 M
52w High $4.45
52w Low $0.34
P/E 3.20
Volume 7.25M
Outstanding Shares 5.11M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $21.85M $8.02M $-4.65M -21.29% $-0.59 $-2.78M
Q4-2024 $4.82B $1.05B $730.94M 15.15% $68.9 $828.07M
Q2-2024 $3.48B $1.21B $-582.18M -16.75% $-118.56 $-440.57M
Q4-2023 $3.59B $971.23M $470.47M 13.12% $86.32 $70.43M
Q2-2023 $3.24B $1.01B $-355.07M -10.95% $-72.72 $-209.41M

What's going well?

The only positive is that interest expense is low, so debt isn't a big problem. There is a small amount of other income helping results.

What's concerning?

Revenue has almost vanished, costs are far too high for the new sales level, and the company is now losing money. Shareholders are also being diluted, making each share less valuable.

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $268.75K $55.36M $51.91M $3.07M
Q4-2024 $335.56M $8.09B $6.9B $933.27M
Q2-2024 $144.65M $5.83B $6.19B $-363.2M
Q4-2023 $132.85M $6.85B $6.63B $210.88M
Q2-2023 $117.73M $6.06B $6.47B $-414.44M

What's financially strong about this company?

Debt and lease obligations are now much lower than before, and there is no goodwill left to write down. The company may have exited risky or unprofitable operations.

What are the financial risks or weaknesses?

Cash is nearly gone, liabilities far exceed assets, and equity has almost disappeared. The company is at serious risk of running out of money.

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-4.65M $-2.37M $-257.25K $629.01K $-1.87M $-2.48M
Q4-2024 $720.37M $-545.96M $-401.84M $1.13B $184.75M $-1.09B
Q2-2024 $-582.18M $-785.72M $381.62M $60.79M $144.65M $-804.41M
Q4-2023 $470.47M $-21.7M $-252.11M $257.27M $-8.42M $-101.3M
Q2-2023 $-355.07M $-610.04M $175.65M $-53.34M $-545.36M $-666.28M

What's strong about this company's cash flow?

The company dramatically reduced its cash burn this quarter, mainly by selling down inventory and collecting receivables. Operating losses are much smaller, and no new shares were issued, so dilution is not a concern right now.

What are the cash flow concerns?

MRM is still losing money and burning cash, with only $226,000 left—barely enough to last another quarter. The improvement came from one-time working capital moves, not from turning the business profitable, and the company is highly dependent on borrowing.

5-Year Trend Analysis

A comprehensive look at MEDIROM Healthcare Technologies Inc.'s financial evolution and strategic trajectory over the past five years.

+ Strengths

MRM’s main strengths are its strong revenue growth, clear turnaround from deep losses to consistent profits, and the repair of its equity base after several stressed years. Operationally, it has improved margins and overhead efficiency, even as it invests in a differentiated health-tech ecosystem built around the MOTHER Bracelet, REMONY platform, salon network, and forward-looking partnerships like World ID. This combination of tangible financial improvement and distinctive strategic positioning gives the company a credible growth narrative.

! Risks

Key risks center on cash and capital structure. Despite accounting profits, the company continues to consume cash in its operations and invests heavily, leading to persistently negative free cash flow and reliance on external financing. Debt levels are high and liquidity, while improved, remains tight, leaving limited buffer against setbacks. Strategically, MRM must execute a complex transformation from a salon operator to a tech- and data-driven platform while facing powerful global competitors and navigating regulatory issues around health data and digital identity. The lack of explicit R&D spending also raises questions about how innovation is being funded and sustained.

Outlook

The outlook is one of cautious opportunity. If MRM can convert its revenue growth and improving margins into positive operating cash flow, gradually reduce its dependence on debt, and successfully scale its health-tech and data platforms, the business could evolve into a much stronger, more resilient enterprise. However, the current financial profile—especially weak cash generation and high leverage—means the path forward is sensitive to execution, funding conditions, and competitive dynamics. The company’s future will largely hinge on turning promising innovation and a unique market position into durable, cash-backed performance.